Welcome to our dedicated page for Oscar Health SEC filings (Ticker: OSCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Oscar Health, Inc. filings document the public-company disclosures of a healthcare technology and health insurance issuer listed on the New York Stock Exchange under Class A common stock symbol OSCR. Its Form 8-K reports cover operating results, guidance updates, Regulation FD disclosures, material agreements and capital-structure transactions, including credit facilities, convertible notes and debt exchanges.
The company’s proxy materials disclose annual meeting matters, board governance, director elections and executive compensation. Other filings address executive employment arrangements, registered securities, risk language tied to competition, artificial intelligence and machine-learning models, internal controls and the company’s use of technology to support Individual & Family plans, +Oscar services and related healthcare marketplace offerings.
Oscar Health, Inc. President of Technology & CTO Mario Schlosser reported two transactions in Class A common stock. He received 189,141 shares as a grant of restricted stock units at a price of $0.00 per share, which are scheduled to vest quarterly in 12 equal installments beginning on June 1, 2026, subject to his continuous service.
He also sold 24,335 shares at a weighted average price of $13.39 per share under a pre-arranged Rule 10b5-1 instruction letter to cover tax withholding tied to earlier equity awards. Following these transactions, he directly owned 514,986 shares, including shares to be issued upon future vesting of restricted stock units.
Oscar Health, Inc. Chief Financial Officer Richard Scott Blackley reported two transactions in Class A common stock. He acquired 134,847 shares as restricted stock units that will vest quarterly in 12 equal installments beginning on June 1, 2026, subject to continued service. On the same date, he sold 19,221 shares at a weighted average price of $13.39 per share under a pre-arranged Rule 10b5-1 instruction to cover tax withholding on earlier equity awards. After these transactions, he directly owned 1,466,660 shares, including shares to be issued upon future RSU vesting.
Richard Scott Blackley filed a Form 144 proposing the sale of 54,850 shares of common stock to be sold on 03/01/2026 through Morgan Stanley Smith Barney LLC. The filing notes restricted stock units vesting under a registered plan as the source, and shows a prior sale of 25,135 shares on 12/02/2025 for $416,989.65.
Mario Schlosser filed a Form 144 reporting proposed sales of Common Stock and recent dispositions. The filing lists a planned disposition of 43,179 Restricted Stock Units vesting under a registered plan on 03/01/2026. It also records multiple open-market sales by Mr. Schlosser totaling several transactions in December 2025 and January 2026 with individual sale sizes and proceeds shown.
Morgan Stanley Smith Barney LLC filed a Rule 144 notice reporting a proposed sale of Common Stock consisting of 14,168 shares tied to "Restricted stock units vesting under a registered plan" expected on 03/01/2026. The filing lists a prior sale by Janet Liang of 7,338 shares on 12/02/2025.
The notice identifies the securities as issuer-held restricted stock units vesting under a registered plan and lists the broker/contact as Morgan Stanley Smith Barney LLC.
OSCR filed a Form 144 notice reporting a proposed sale of 35,961 shares of Common Stock tied to restricted stock units vesting under a registered plan on 03/01/2026.
The filing also records a prior sale by Adam McAnaney of 1,852 shares on 12/02/2025 for $30,724.68.
Oscar Health, Inc. is confirming that its previously issued full-year 2026 financial guidance remains in place as it participates in the 2026 Raymond James Institutional Investors Conference on March 2, 2026. The guidance being reaffirmed was first provided in its February 10, 2026 press release covering fourth-quarter and full-year 2025 results.
The company also reminds readers that these expectations are forward-looking statements subject to risks and uncertainties described in its Annual Report on Form 10-K for the year ended December 31, 2025 and other SEC filings.
Oscar Health, Inc. investors Marc Stad and Dragoneer Investment Group, LLC report a small passive ownership stake in the company’s Class A Common Stock. They beneficially own 657,435 shares, representing about 0.3% of the class, based on 229,010,000 shares outstanding as of October 31, 2025. All voting and dispositive power over these shares is shared, with no sole authority reported. The filing states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Oscar Health.
Oscar Health, Inc. describes itself as a technology-focused health insurer centered on the Affordable Care Act individual market. The company reports approximately 2.0 million effectuated members as of December 31, 2025, with total membership of 2,042,449 compared with 1,676,970 a year earlier.
Membership is heavily concentrated in Florida with 1,179,934 members, followed by Texas at 358,910 and Georgia at 218,746. Oscar notes that about 93% of 2025 premiums came from CMS via advance premium tax credits, with 7% paid directly by members, underscoring its reliance on ACA subsidies.
The company highlights its proprietary full-stack technology platform, virtual care, and +Oscar Campaign Builder, which serves nearly 0.6 million client lives in addition to its insurance members. Oscar expanded into 20 states for 2026 and acquired Lucie, IHC Specialty Benefits, and Healthinsurance.org to support its ICHRA and consumer marketplace strategy.
As of June 30, 2025, the approximate value of Oscar’s Class A common stock held by non‑affiliates was $4.5 billion, based on a New York Stock Exchange closing price of $21.44 per share. Shares outstanding as of January 31, 2026 were 262,157 thousand Class A and 35,591 thousand Class B, and the company employed about 2,305 people.
Oscar Health, Inc. reported strong top-line growth but a sharp swing back to losses in 2025 and set an optimistic 2026 outlook, while adding a large new credit facility.
Full-year 2025 total revenue rose to $11.7 billion from $9.2 billion, driven by higher membership. However, the medical loss ratio worsened to 87.4% from 81.7%, and earnings from operations fell to a $396.4 million loss from $57.3 million of earnings. Net loss attributable to Oscar was $443.2 million versus net income of $25.4 million in 2024, and Adjusted EBITDA deteriorated to a $279.8 million loss from $199.2 million of positive Adjusted EBITDA.
Membership reached about 2.0 million as of December 31, 2025, with Individual and Small Group members rising to just over 2.0 million. For 2026, Oscar guides to total revenue of $18.7–$19.0 billion, a medical loss ratio of 82.4–83.4%, an SG&A ratio of 15.8–16.3%, and $250–$450 million of earnings from operations, implying a planned return to profitability. The company also entered into a new $475 million secured revolving credit facility, expandable by up to $100 million, maturing on February 6, 2029, with financial covenants tied to premiums, liquidity, leverage, and coverage ratios.